MiNK Therapeutics, Inc. cotiza a 10.23 USD y tiene una capitalización bursátil de $52M. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud
MiNK Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, manufacture, and commercialization of allogeneic, off-the-shelf, and invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. The company develops agenT-797, an off-the…
| Periodo | 2026-08 | 2026-05 | 2026-03 | 2025-11 |
|---|---|---|---|---|
| Real | — | $-0.57 | $-0.56 | $-0.65 |
| Estimado | $-0.60 | $-0.77 | $-0.68 | $-0.85 |
| Sorpresa | — | +26.0% | +17.6% | +23.5% |
| Métrica | INKT | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | — | 57.0% | — |
| Operating Margin | — | -38.6% | — |
| Net Margin | — | -33.6% | — |
| FCF Margin | — | -13.9% | — |
| ROE | — | -40.4% | — |
| ROA | -87.8% | -32.0% | -55.7% |
| Current Ratio | 1.06 | 2.84 | -1.78 |
| Debt / Equity | — | 0.28 | — |